Modern Diagnostic and Treatment Methods for Myelodysplastic Syndromes
Keywords:
myelodysplastic syndrome, hematopoiesis, cytopenia, NGS, IPSS-M, azacitidine, luspatercept, transplantationAbstract
Myelodysplastic syndromes are clonal diseases of hematopoietic stem cells characterized by ineffective hematopoiesis, peripheral cytopenias, and a risk of transformation into acute myeloid leukemia. In recent years, significant advances in molecular genetics, cytogenetics, and targeted therapy have fundamentally altered the principles of MDS diagnosis and treatment. This article analyzes the pathogenesis of MDS, modern diagnostic algorithms, the importance of molecular biomarkers, and the innovative treatment methods currently being used.
References
[1] World Health Organization, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 5th ed. Geneva, Switzerland: WHO, 2022.
[2] National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 2.2024. Plymouth Meeting, PA, USA: NCCN, 2024.
[3] U. Platzbecker et al., “European LeukemiaNet recommendations for the diagnosis and management of myelodysplastic syndromes in adults,” Blood, vol. 143, no. 12, pp. 1105–1121, Mar. 2024.
[4] American Society of Hematology, “ASH clinical practice guidelines for the management of myelodysplastic syndromes,” Blood Advances, vol. 7, no. 4, pp. 612–625, Feb. 2023.
[5] B. Malcovati et al., “Valedictory International Prognostic Scoring System for Myelodysplastic Syndromes: IPSS-M,” NEJM Evidence, vol. 1, no. 7, p. EVIDoa2200008, Jul. 2022.
[6] R. Bejar, “Clinical implications of somatic mutations in myelodysplastic syndromes,” Blood, vol. 141, no. 9, pp. 981–992, Mar. 2023.
[7] G. Garcia-Manero, “Current and emerging therapies in myelodysplastic syndromes,” American Journal of Hematology, vol. 99, no. 4, pp. 675–692, Apr. 2024.
[8] P. Fenaux et al., “Luspatercept for the treatment of anemia in myelodysplastic syndromes,” The New England Journal of Medicine, vol. 382, no. 2, pp. 140–151, Jan. 2020.
[9] D. P. Steensma, “The changing landscape of classification and prognosis in MDS,” Leukemia, vol. 37, no. 5, pp. 945–957, May 2023.
[10] M. Cazzola, “Myelodysplastic syndromes: Biological and clinical characteristics,” Blood, vol. 135, no. 13, pp. 1006–1014, Mar. 2020.
[11] T. Haferlach et al., “Landscape of genetic mutations in 944 patients with myelodysplastic syndromes,” Leukemia, vol. 28, no. 2, pp. 241–247, Feb. 2014.
[12] H. Döhner et al., “Acute myeloid leukemia and myelodysplastic syndromes: ELN 2022 recommendations,” Blood, vol. 140, no. 12, pp. 1345–1377, Sep. 2022.
[13] E. Hellström-Lindberg et al., “Management of anemic patients with myelodysplastic syndromes,” The Lancet Haematology, vol. 10, no. 6, pp. e450–e462, Jun. 2023.
[14] A. M. Zeidan et al., “Hypomethylating agents in myelodysplastic syndromes: Current standards and next steps,” Cancer Treatment Reviews, vol. 118, p. 102570, Jul. 2023.
[15] J. Boultwood et al., “The 5q- syndrome: From pathogenesis to therapy,” Blood, vol. 138, no. 24, pp. 2453–2464, Dec. 2021.
